- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06421597
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID)
May 14, 2024 updated by: Odense University Hospital
Previous studies have shown that there is a large inter-individual variability in the degree of bone loss during glucocorticoid treatment, and while some patients experience extensive bone loss other patients' bone mass remains stable.
The aim of the study is to find a biomarker that can be used to identify individuals at risk of glucocorticoid-induced bone loss.
The study will include 36 healthy volunteers, that will be randomized to receive either glucocorticoid treatment or placebo.
During the study blood samples, bone marrow samples, bone tissue samples, and adipose tissue samples are taken and a mixed meal test is performed.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Catharina Vind Nielsen, MD
- Phone Number: +45 21351124
- Email: catharina.vind.nielsen@rsyd.dk
Study Locations
-
-
-
Esbjerg, Denmark, 6700
- Hospital of South West Jutland
-
Contact:
- Catharina Vind Nielsen, MD
- Phone Number: +45 21351124
- Email: catharina.vind.nielsen@rsyd.dk
-
Odense C, Denmark, 5000
- Odense University Hospital
-
Contact:
- Catharina Vind Nielsen, MD
- Phone Number: +45 21351124
- Email: catharina.vind.nielsen@rsyd.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and women aged 18-50 years.
Exclusion Criteria:
- Uncontrolled thyrotoxicosis
- Chronic kidney disease (eGFR <30)
- Known Cushing's syndrome
- Previous gastric bypass and/or known ongoing malabsorption
- Severe covid-19 in the last 3 month (defined as needing dexamethasone treatment)
- Use of oral or inhaled glucocorticoids within the past year
- Menopause (defined as 1 year without menstrual bleeding)
- Pregnancy (defined as elevated HCG)
- Ongoing infection
- Allergy to prednisolone or one of the excipients
- Systematic fungal infections
- Vaccination with living or weaken viral or bacterial vaccines in patient who or immunocompromised. In these cases, prednisolone treatment should not be administered two weeks before and after vaccination
- Not able to provide informed consent (e.g., dementia, not able to understand Danish).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
|
Placebo treatment for seven days
|
Experimental: Prednisolone group
|
prednisoline 25 mg/day for seven days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procollagen type 1 N-terminal propeptide (P1NP)
Time Frame: Baseline to day 8
|
Changes in the level of the bone turnover marker P1NP in peripheral blood from baseline to day 8
|
Baseline to day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collagen 1 cross link C-terminal telopeptide (CTX)
Time Frame: Baseline to day 8 and 15
|
Changes in the level of the bone turnover marker CTX in peripheral blood from baseline to day 8 and 15
|
Baseline to day 8 and 15
|
P1NP (baseline to day 15)
Time Frame: Baseline to day 15
|
Changes in the level of the bone turnover marker P1NP in peripheral blood from baseline to day 15
|
Baseline to day 15
|
Concentration of Glucocorticoid metabolites
Time Frame: Baseline to day 8
|
Changes in the levels of glucocorticoid metabolites in blood from baseline to day 8
|
Baseline to day 8
|
Adipose tissue
Time Frame: Baseline to day 8
|
Changes in gene expression in abdominal and gluteal subcutaneous adipose tissue from baseline to day 8
|
Baseline to day 8
|
Bone tissue
Time Frame: Baseline to day 8
|
Changes in gene expression in bone tissue from baseline to day 8
|
Baseline to day 8
|
Glucose
Time Frame: Baseline to day 8
|
Changes in glucose levels during a mixed meal test from baseline to day 8
|
Baseline to day 8
|
C-peptid
Time Frame: Baseline to day 8
|
Changes in c-peptid levels during a mixed meal test from baseline to day 8
|
Baseline to day 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarker
Time Frame: Baseline
|
Untargeted proteomics will be used to try to identify a biomarker for individuals at risk of glucocorticoid induced bone loss
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Morten Frost, MD, Odense University Hospital
- Principal Investigator: Claus Bogh Juhl, MD, Hospital of South West Jutland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
May 3, 2024
First Submitted That Met QC Criteria
May 14, 2024
First Posted (Actual)
May 20, 2024
Study Record Updates
Last Update Posted (Actual)
May 20, 2024
Last Update Submitted That Met QC Criteria
May 14, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-506949-27-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be shared with other researchers other than collaborators.
Since the data contains personal information from the study participants
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis Secondary
-
University of GuadalajaraHospital Civil de GuadalajaraCompleted
-
Beni-Suef UniversityCompletedHigh-Intensity Laser Therapy Versus Shockwave Therapy in Osteoporotic Long Term Hemiparetic PatientsOsteoporosis SecondaryEgypt
-
Creighton UniversityGlaxoSmithKlineCompletedOsteoporosis | Secondary Hyperparathyroidism
-
Hospital Regional 1o de OctubreUniversidad Nacional Autonoma de Mexico; National Polytechnic Institute, MexicoCompletedHyperparathyroidism, Primary | Hyperparathyroidism, Secondary | Hypovitaminosis D | Postmenopause | Postmenopausal OsteoporosisMexico
-
Odense University HospitalAarhus University Hospital; Aalborg University Hospital; Hospital of South West... and other collaboratorsActive, not recruitingDiabetes Mellitus, Type 1 | Osteoporosis SecondaryDenmark
-
Mayo ClinicCompletedMetabolic Bone Disease | Transplant-Related Disorder | Secondary OsteoporosisUnited States
-
James J. Peters Veterans Affairs Medical CenterKessler Institute for RehabilitationTerminatedSpinal Cord Injury | Secondary OsteoporosisUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
Clinical Trials on Prednisolone
-
Children's Hospital of PhiladelphiaCompleted
-
Assiut UniversityCompleted
-
Sparrow PharmaceuticalsRecruitingPolymyalgia RheumaticaGermany
-
IsalaCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
Postgraduate Institute of Medical Education and...Completed
-
Postgraduate Institute of Medical Education and...CompletedPost COVID-19 Diffuse Lung DiseaseIndia
-
Nanjing University School of MedicineCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity Medical Center Groningen; Imperial College London; University Hospitals... and other collaboratorsTerminatedWegener's Granulomatosis | Microscopic PolyangiitisUnited Kingdom
-
Hamamatsu UniversityCompletedChronic Disease | Eosinophilic PneumoniaJapan
-
Institute of Child HealthUnknown